MedTrace Logo

Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

NCT05167409 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-07-22

Study results available
· View outcomes & findings →

Summary

This Phase 2 clinical study will evaluate evorpacept (ALX148) in combination with cetuximab and pembrolizumab for refractory microsatellite stable metastatic colorectal cancer

Conditions

Interventions

DRUG

Evorpacept (ALX148)

IV QW

DRUG

Cetuximab

IV QW

DRUG

Pembrolizumab

IV Q3W

Sponsors & Collaborators

  • ALX Oncology Inc.

    collaborator INDUSTRY

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Criterium, Inc.

    collaborator INDUSTRY

  • Academic GI Cancer Consortium (AGICC)

    collaborator OTHER

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Wells Messersmith, MD · University of Colorado, Denver

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-28
Primary Completion
2024-10-30
Completion
2024-10-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05167409 on ClinicalTrials.gov